TG Therapeutics (NASDAQ:TGTX) Upgraded by StockNews.com to Hold Rating

TG Therapeutics (NASDAQ:TGTX) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. HC Wainwright boosted their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. TD Cowen started coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, The Goldman Sachs Group boosted their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Trading Up 4.3 %

Shares of TGTX opened at $32.02 on Friday. TG Therapeutics has a fifty-two week low of $12.84 and a fifty-two week high of $36.84. The firm has a market cap of $4.98 billion, a price-to-earnings ratio of -320.17 and a beta of 2.25. The firm has a 50 day moving average price of $28.56 and a 200-day moving average price of $23.35. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter in the previous year, the company earned $0.73 earnings per share. The business’s quarterly revenue was down 49.4% on a year-over-year basis. As a group, equities research analysts forecast that TG Therapeutics will post 0.17 earnings per share for the current year.

Insider Activity

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Several large investors have recently modified their holdings of TGTX. NBC Securities Inc. increased its stake in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of TG Therapeutics during the second quarter valued at approximately $35,000. Blue Trust Inc. increased its position in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in TG Therapeutics in the 3rd quarter worth approximately $53,000. Finally, Values First Advisors Inc. bought a new position in TG Therapeutics in the 3rd quarter valued at approximately $58,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.